Agios is the first biopharmaceutical company dedicated to drug discovery based on targeting cancer metabolism, which offers the potential for a new class of oncology therapeutics targeting metabolic pathways critical to cancer cell growth, proliferation and survival. With new research showing that cancer cells become addicted to using more nutrients than normal cells to promote their rapid growth, there is an unprecedented opportunity to create a new class of oncology therapeutics that target a fundamental and ubiquitous mechanism in cancer cells. Agios’ founders are world-renowned authorities in cancer who are pioneers responsible for key advances in cancer metabolism.

Flagship General Partner Doug Cole is on the Board of Directors.

www.agiospharma.com